| Serial Number | 77673768 |
| Word Mark | OXFORD BIOMEDICA |
| Filing Date | Thursday, February 19, 2009 |
| Status | 710 - CANCELLED - SECTION 8 |
| Status Date | Friday, January 5, 2018 |
| Registration Number | 3968293 |
| Registration Date | Tuesday, May 31, 2011 |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, March 15, 2011 |
| Disclaimer with Predetermined Text | "OXFORD" |
| Goods and Services | Chemicals for use in industry and science; enzymes for scientific and research purposes; biochemicals, namely, precursors for in vitro genetic engineering use; polypeptides for in vitro research use, monoclonal antibodies for in vitro scientific or research use; chemicals for use in the purification of proteins for in vitro use; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; micro-organisms for laboratory and scientific research use, viruses for laboratory and scientific research use, cell cultures for laboratory and scientific research use, plasmids and cultures of micro-organisms for laboratory and scientific research use, nucleic acid sequences for laboratory and scientific research use, cloning vehicles in the nature of plasmids, microbes and chemical reagents for DNA cloning for laboratory and scientific research use, chemicals for laboratory, scientific and biotechnology research and development and recombinant nucleic acid variations thereof for laboratory and scientific research use, namely, in vitro and in vivo use |
| Goods and Services | Gene therapy and prophylactic products, namely, gene delivery pharmaceuticals; small molecules, vaccines, biologics, enzymes and enzyme preparations all for medical treatment purposes; pharmaceuticals for medical purposes for the delivery of genes to cells; viral, retroviral and non-viral vectors, all for medical purposes in gene therapy; pharmaceutical and biochemical preparations for the treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders; pharmaceutical and biochemical preparations for contraceptive purposes; pre-filled vials for medical purposes and for pharmaceutical and biochemical preparations, for use in gene therapy and for the treatment or prevention of cancer, infectious disease, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders |
| Goods and Services | Instruments and apparatus for the administration of pharmaceutical, gene therapy and/or vaccine preparations and substances, namely, medical syringes and injectors for medical purposes |
| Goods and Services | Scientific, pharmaceutical and medical research and development; genetic engineering services, biotechnology services, namely, research and development for new products in the field of biotechnology, advisory services relating to gene therapy products and clinical trials, conducting clinical trials |
| Goods and Services | Medical services; advisory services relating to vaccination regimes; advisory services relating to the treatment, relief and/or prevention of cancer, infectious diseases, fungal diseases, diseases caused by parasites, namely, hookworms, pinworms, roundworms, tapeworms, flukes, giardia, entameoba, cryptosporidium, toxoplasmosis, sleeping sickness, trichuriasis, isosporiasis, malaria, parasitic skin disease and leishmaniasis, eye diseases, diseases of the central and peripheral nervous systems, namely, ataxia, dementia, epilepsy, Alzheimer's, cerebral palsy, stroke, motor neuron disease, Parkinson's disease, spinal injury, avulsion injury and peripheral neuropathies, cardiovascular disease, diseases affecting the immune system, namely, cancer, Crohn's disease, AIDS, HIV, lupus, celiac disease, diabetes, Grave's disease, Guillain-Barré syndrome, Addison's disease, Hashimoto's disease, myasthenia gravis, narcolepsy, pernicious anaemia, rheumatoid arthritis, psoriasis, ulcerative colitis, immunodeficiency and inflammatory diseases, inherited diseases, namely, genetic disorders, hemophilia, cystic fibrosis and Huntingdon's, single gene disorders, bone and blood diseases and reproductive system disorders and contraceptives |
| Pseudo Mark | OXFORD BIO MEDICAL |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 2 - Sec. 8 - Entire Registration |
| Class Status Date | Friday, January 5, 2018 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 2 - Sec. 8 - Entire Registration |
| Class Status Date | Friday, January 5, 2018 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials. |
| US Class Codes | 026, 039, 044 |
| Class Status Code | 2 - Sec. 8 - Entire Registration |
| Class Status Date | Friday, January 5, 2018 |
| Primary Code | 010 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 2 - Sec. 8 - Entire Registration |
| Class Status Date | Friday, January 5, 2018 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 2 - Sec. 8 - Entire Registration |
| Class Status Date | Friday, January 5, 2018 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Oxford BioMedica plc |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 11 - Company |
| Address | Oxford OX44GA GB |
| Party Name | Oxford BioMedica plc |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 11 - Company |
| Address | Oxford OX44GA GB |
| Party Name | Oxford BioMedica plc |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 11 - Company |
| Address | Oxford OX44GA GB |
| Event Date | Event Description |
| Friday, January 5, 2018 | CANCELLED SEC. 8 (6-YR) |
| Tuesday, May 31, 2011 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, March 15, 2011 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, March 15, 2011 | PUBLISHED FOR OPPOSITION |
| Tuesday, February 8, 2011 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| Monday, January 31, 2011 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Monday, January 31, 2011 | EXAMINER'S AMENDMENT ENTERED |
| Monday, January 31, 2011 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Monday, January 31, 2011 | EXAMINERS AMENDMENT E-MAILED |
| Monday, January 31, 2011 | EXAMINERS AMENDMENT -WRITTEN |
| Thursday, January 6, 2011 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, January 6, 2011 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, January 6, 2011 | ASSIGNED TO LIE |
| Thursday, December 9, 2010 | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
| Monday, June 14, 2010 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED |
| Monday, June 14, 2010 | INQUIRY TO SUSPENSION E-MAILED |
| Monday, June 14, 2010 | SUSPENSION INQUIRY WRITTEN |
| Friday, December 11, 2009 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Friday, December 11, 2009 | LETTER OF SUSPENSION E-MAILED |
| Friday, December 11, 2009 | SUSPENSION LETTER WRITTEN |
| Tuesday, December 1, 2009 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Tuesday, December 1, 2009 | LETTER OF SUSPENSION E-MAILED |
| Tuesday, December 1, 2009 | SUSPENSION LETTER WRITTEN |
| Friday, November 20, 2009 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, November 20, 2009 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, November 20, 2009 | ASSIGNED TO LIE |
| Monday, November 9, 2009 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, May 11, 2009 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, May 11, 2009 | NON-FINAL ACTION E-MAILED |
| Monday, May 11, 2009 | NON-FINAL ACTION WRITTEN |
| Monday, May 11, 2009 | ASSIGNED TO EXAMINER |
| Tuesday, February 24, 2009 | NOTICE OF PSEUDO MARK MAILED |
| Monday, February 23, 2009 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Monday, February 23, 2009 | NEW APPLICATION ENTERED IN TRAM |